Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Common Equity (2018 - 2025)

Historic Common Equity for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $18.1 million.

  • Exagen's Common Equity rose 4095.43% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 4095.43%. This contributed to the annual value of $9.5 million for FY2024, which is 5796.25% down from last year.
  • Latest data reveals that Exagen reported Common Equity of $18.1 million as of Q3 2025, which was up 4095.43% from $21.0 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Common Equity ranged from a high of $101.5 million in Q1 2021 and a low of $6.4 million during Q1 2025
  • In the last 5 years, Exagen's Common Equity had a median value of $31.9 million in 2023 and averaged $43.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 10417.1% in 2021, then plummeted by 6797.06% in 2025.
  • Over the past 5 years, Exagen's Common Equity (Quarter) stood at $84.9 million in 2021, then plummeted by 50.01% to $42.5 million in 2022, then crashed by 46.55% to $22.7 million in 2023, then plummeted by 57.96% to $9.5 million in 2024, then soared by 90.13% to $18.1 million in 2025.
  • Its Common Equity stands at $18.1 million for Q3 2025, versus $21.0 million for Q2 2025 and $6.4 million for Q1 2025.